We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+23.13%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$586M
AUM Growth
+$72M
Cap. Flow
+$10.1M
Cap. Flow %
1.72%
Top 10 Hldgs %
54.34%
Holding
53
New
16
Increased
10
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$29.5M
2
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$18.3M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$15.9M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$15.1M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$13.8M

Top Sells

Rank Stock Value
1
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$26.9M
2
RXDX
Ignyta, Inc.
RXDX
+$15.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$11.3M
4
RNAC icon
Cartesian Therapeutics
RNAC
+$10.5M
5
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$9.49M

Sector Composition

Rank Sector Weight
1 Healthcare 87.34%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBVT
26
DBV Technologies
DBVT
$799M
$7.7M 1.31%
31,314
-13,775
-31% -$3.98M
XLRN
27
DELISTED
Acceleron Pharma
XLRN
$7.35M 1.25%
173,124
+3,124
+2% +$117K
INCY icon
28
Incyte
INCY
$24.2B
$6.66M 1.14%
+70,323
New +$7.35M
CDTX
29
DELISTED
Cidara Therapeutics
CDTX
$5.44M 0.93%
+40,000
New +$6.07M
ACOR
30
PUT
DELISTED
Acorda Therapeutics
ACOR
$4.29M 0.73%
+1,667
New +$4.74M
CRBP icon
31
Corbus Pharmaceuticals
CRBP
$166M
$4.26M 0.73%
+20,000
New +$4.28M
AMRN
32
Amarin Corp
AMRN
$299M
$4.24M 0.72%
52,841
– –
JNCE
33
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.73M 0.64%
+292,673
New +$4.3M
KDMN
34
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.04M 0.52%
+840,303
New +$3M
MYOV
35
DELISTED
Myovant Sciences Ltd.
MYOV
$2.03M 0.35%
160,530
-67,478
-30% -$905K
RNAC icon
36
Cartesian Therapeutics
RNAC
$229M
$1.75M 0.3%
5,930
-24,132
-80% -$10.5M
DERM
37
DELISTED
Dermira, Inc.
DERM
$1.21M 0.21%
+43,637
New +$1.16M
CNXR
38
DELISTED
Connecture, Inc.
CNXR
$660K 0.11%
4,127,232
– –
STRM
39
DELISTED
Streamline Health Solutions
STRM
$220K 0.04%
8,676
– –
ALNY icon
40
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-250,000
Closed -$29.4M
APYX icon
41
Apyx Medical
APYX
$173M
– –
-1,829,441
Closed -$6.18M
ARDX icon
42
Ardelyx
ARDX
$1.22B
– –
-123,316
Closed -$691K
MCRB icon
43
PUT
Seres Therapeutics
MCRB
$46.8M
– –
-13,750
Closed -$4.41M
PTCT icon
44
CALL
PTC Therapeutics
PTCT
$5.68B
– –
-460,000
Closed -$9.21M
SRPT icon
45
Sarepta Therapeutics
SRPT
$1.57B
– –
-250,000
Closed -$11.3M
UTHR icon
46
CALL
United Therapeutics
UTHR
$25.8B
– –
-300,000
Closed -$35.2M
VIRX
47
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-41,649
Closed -$2.83M
AGRX
48
DELISTED
Agile Therapeutics
AGRX
– –
-182
Closed -$1.62M
ADMS
49
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-256,340
Closed -$5.43M
SGYP
50
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-3,273,509
Closed -$9.49M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2017 Portfolio in Review

As of Q4 2017, Great Point Partners held 53 positions worth $586M, up 14% from $514M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Great Point Partners's Q4 2017 filing shows 16 new, 10 increased, 8 reduced and 14 closed positions. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 410,900 shares worth $21.1M. The largest sale was Concert Pharmaceuticals, Inc., an estimated $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 69% a quarter earlier, followed by Technology.

  • Great Point Partners's largest Q4 2017 buy was Spark Therapeutics, Inc. Common Stock: 410,900 shares worth $21.1M.
  • Great Point Partners added most to Sio Gene Therapies Inc. Common Stock in Q4 2017, an estimated $15.9M increase.
  • Great Point Partners's biggest Q4 2017 reduction was Concert Pharmaceuticals, Inc., cutting an estimated $26.9M.
  • Great Point Partners fully exited Ignyta, Inc. in Q4 2017, selling an estimated $15.3M.
  • Great Point Partners's ten largest holdings make up 54% of its $586M portfolio in Q4 2017.
  • Great Point Partners opened 16 new positions and closed 14 in Q4 2017.
  • Great Point Partners's portfolio value rose 14% quarter-over-quarter to $586M.

Based on Great Point Partners's 13F filing for Q4 2017, filed 14 Feb 2018.